Anixa Biosciences (ANIX)
(Delayed Data from NSDQ)
$2.91 USD
-0.11 (-3.64%)
Updated May 7, 2024 04:00 PM ET
After-Market: $2.93 +0.02 (0.69%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.91 USD
-0.11 (-3.64%)
Updated May 7, 2024 04:00 PM ET
After-Market: $2.93 +0.02 (0.69%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Zacks News
Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug
by Zacks Equity Research
Dermata (DRMA) announces reaching an agreement with the FDA to begin a late-stage pivotal clinical program for its acne treatment candidate, DMT310. The stock rises 7%.
Ardelyx (ARDX) Up on Xphozah's Orphan Tag for Hyperphosphatemia
by Zacks Equity Research
Ardelyx (ARDX) announces that the FDA has granted orphan drug designation to Xphozah for the treatment of pediatric hyperphosphatemia. The stock rises 4%.
Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline Updates
by Zacks Equity Research
Kodiak (KOD) reports better-than-expected third-quarter 2023 results and provides updates regarding its pipeline development plans.
Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies
by Zacks Equity Research
Moleculin (MBRX) announces positive interim data from its early-mid-stage studies of Annamycin in blood and lung cancer indications, along with encouraging third-quarter results. The stock rises 7%.
Immunovant (IMVT) Q2 Earnings Top Estimates, Pipeline in Focus
by Zacks Equity Research
Immunovant (IMVT) reports better-than-expected fiscal second-quarter 2023 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.
Intellia (NTLA) Beats on Q3 Earnings, Provides Pipeline Update
by Zacks Equity Research
Intellia (NTLA) reports mixed third-quarter 2023 results. Management provides developmental and regulatory updates on its key pipeline candidates.
FATE Q3 Earnings Beat on Lower Expenses, Revenues Fall Y/Y
by Zacks Equity Research
FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating expenses. The stock rises about 5% in the after-market hours.
Catalyst (CPRX) Q3 Earnings Miss, Sales Top, '23 View Up
by Zacks Equity Research
Catalyst (CPRX) reports mixed third-quarter results. Firdapse and Fycompa sales continue to boost revenues. Management raises 2023 financial guidance. The stock gains 6% in the after-market hours.
Vertex (VRTX) Q3 Earnings Beat, Sales Miss, Raises '23 View
by Zacks Equity Research
Vertex's (VRTX) third-quarter results reflect a year-over-year increase in revenues. The company raises its net product sales guidance for 2023.
Deciphera (DCPH) Stock Gains 17% on Q3 Earnings & Sales Beat
by Zacks Equity Research
Deciphera (DCPH) reports better-than-expected third-quarter 2023 results, wherein earnings and revenues beat estimates, driven by increased Qinlock sales. The stock rises 17%.
Dr. Reddy's (RDY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Dr. Reddy's (RDY) reports better-than-expected fiscal second-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in core businesses in North America and Europe.
Blueprint (BPMC) Stock Gains 26% on Q3 Earnings & Sales Beat
by Zacks Equity Research
Blueprint (BPMC) climbs 26% on better-than-expected third-quarter 2023 results, driven by increased Ayvakit sales following the drug's label expansion in the United States.
Bristol Myers' (BMY) Opdivo SC Meets Kidney Cancer Study Goals
by Zacks Equity Research
Bristol Myers' (BMY) subcutaneous formulation of Opdivo, developed using Halozyme's Enhanze technology, meets noninferiority goals in a late-stage kidney cancer study compared with intravenous Opdivo.
Ardelyx (ARDX) Up on FDA Nod to Xphozah for Hyperphosphatemia
by Zacks Equity Research
Ardelyx (ARDX) gets FDA approval for Xphozah to reduce serum phosphorus in adult patients with kidney disease on dialysis as an add-on therapy. The stock of the company climbs 13%.
Inovio Pharma (INO) Stock Surges 19% This Month: Here's Why
by Zacks Equity Research
Inovio Pharma (INO) rises 19% this month after the FDA issues positive feedback on data from a phase I/II study on a rare respiratory disease candidate, INO-3107, which can be used to file a BLA.
Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus Drug
by Zacks Equity Research
Nkarta (NKTX) rallies 112% on FDA nod to begin the clinical development of its investigational candidate, NKX019, for the treatment of lupus nephritis.
Biomea (BMEA) Doses First Patient in Leukemia Study, Stock Up
by Zacks Equity Research
Biomea (BMEA) successfully doses the first patient in its phase I study of BMF-500 to treat adult patients with acute leukemia. The company's stock rises 6.7% on the news.
Here's Why You May Invest in CRISPR Therapeutics (CRSP) Stock
by Zacks Equity Research
Here we discuss some reasons why investing in CRISPR Therapeutics (CRSP) stock now may turn out to be a more prudent move than ever.
Bears are Losing Control Over ANIXA BIOSCIENCES INC (ANIX), Here's Why It's a 'Buy' Now
by Zacks Equity Research
ANIXA BIOSCIENCES INC (ANIX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
BioCardia (BCDA) Up on Plans for Second Heart Failure Study
by Zacks Equity Research
BioCardia (BCDA) completes enrollment in a pivotal phase III study on its CardiAMP cell therapy for the treatment of heart failure. It plans to begin a second study with responders from the initial study.
ANIXA BIOSCIENCES INC (ANIX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Gilead (GILD) Ends Myelodysplastic Syndromes Study on Magrolimab
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) discontinues phase III ENHANCE study, evaluating the potential of magrolimab as a treatment for higher-risk myelodysplastic syndromes, due to futility based on a planned analysis.
Vir Biotechnology (VIR) Down on Influenza Study Failure
by Zacks Equity Research
Vir Biotechnology (VIR) crashes after the phase II study evaluating VIR-2482 for preventing symptomatic influenza A illness fails to meet goals.
Apellis (APLS) Plunges on Safety Issues With Eye Treatment
by Zacks Equity Research
Apellis (APLS) suffers a setback on reports of six events of retinal vasculitis (or inflammation) following treatment with Syfovre (pegcetacoplan injection).
Novartis (NVS) Q2 Earnings & Revenues Top, Guidance Raised
by Zacks Equity Research
Novartis (NVS) beats on earnings and sales in the second quarter and raises its annual guidance on strong momentum.